MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

NCT06197126NOT_YET_RECRUITINGOBSERVATIONAL

Summary

This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.

Key Facts

Lead Sponsor

Fujian Cancer Hospital

Enrollment

200

Start Date

2024-01-01

Completion Date

2027-12-31

Study Type

OBSERVATIONAL

Official Title

A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy

Interventions

Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .

Conditions

Cervical CancerRadiotherapyPrognostic ModelMRI

Eligibility

Age Range

20 Years – 85 Years

Sex

FEMALE

Inclusion Criteria:

* (1) pathologically confirmed CC, (2) initially treated in our center

Exclusion Criteria:

* (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up

Outcome Measures

Primary Outcomes

overall survival

the interval from diagnostic day to death or the last follow-up

Time frame: 1-36 months

Secondary Outcomes

progression-free survival

the interval from diagnostic day to death, the last follow-up, or the onset of regional recurrence or distant metastasis

Time frame: 1-36 months

Locations

Fujian Cancer Hospital, Fuzhou, China

Linked Investigators

Jacob Christian Lindegaard

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy